A recent Oncology digest,
as sent to subscribers

Study Type: Commentary / reflective piece

Key Question: How does cumulative emotional exposure affect oncology clinicians over the course of their careers?

Key Findings:

• Describes an intangible, accumulating psychological burden resulting from repeated patient loss in oncology practice
• Each clinical encounter is framed as leaving a lasting emotional imprint on the clinician, irrespective of clinical outcome
• The piece argues this burden remains largely invisible within professional and institutional frameworks

Clinical Relevance: Oncology clinicians in the NHS face high rates of moral distress and burnout; this piece draws attention to the unacknowledged psychological cost of sustained exposure to patient death and suffering, relevant to workforce wellbeing strategies.

Limitations: Not applicable — reflective commentary without primary data. --- *Note: This is a reflective/literary piece. No quantitative findings, study population, or methodology are present. The summary is necessarily interpretive based on the abstract provided.*

Study Type: Retrospective multicentre cohort study

Key Question: Does the pattern of HLA mismatches between donor and recipient predict immune evasion via genomic HLA loss at leukaemia relapse after allogeneic HCT?

Key Findings:

• HLA loss occurred in 15.6% of 533 post-HCT relapses overall, but was markedly higher after haploidentical transplants (28.7%) versus unrelated donor (7.2%) or cord blood (2.7%)
• HLA mismatches located on the same haplotype (cis configuration) conferred a 27.6% HLA loss rate versus 5.4% when mismatches were on different haplotypes (trans; p<0.0001)
• At relapse, HLA loss abrogated efficacy of original donor lymphocyte infusions; second allo-HCT from a different donor conferred a significant survival advantage

Clinical Relevance: This directly informs donor selection strategy in UK transplant practice, with a validated phasing tool enabling pre-transplant risk stratification for HLA loss-mediated relapse.

Limitations: Retrospective design with potential selection bias across 27 heterogeneous international centres.

Study Type: RCT (randomised phase II/III trial — long-term follow-up analysis)

Key Question: Is weekly cisplatin (40 mg/m² ×7) non-inferior to 3-weekly cisplatin (100 mg/m² ×3) when combined with postoperative radiotherapy in high-risk locally advanced head and neck squamous cell carcinoma?

Key Findings:

• At median follow-up of 5.6 years, 5-year OS was 71.2% (weekly) vs 58.7% (3-weekly); HR 0.76 (95% CI 0.52–1.12), confirming non-inferiority
• 5-year RFS and local RFS were numerically superior in the weekly arm, though formal superiority was not established
• No late toxicity differed by >10% between arms

Clinical Relevance: Weekly cisplatin-based CRT is commonly used in UK postoperative head and neck oncology practice; this 5-year data provides durable evidence supporting its use over 3-weekly cisplatin without compromising survival or increasing late toxicity.

Limitations: The trial was conducted in a Japanese population, limiting direct generalisability to UK/Western practice.

Study Type: Single-arm, phase II trial

Key Question: Does first-line disitamab vedotin (HER2-directed ADC) combined with tislelizumab (PD-1 inhibitor) and S-1 offer meaningful efficacy in HER2-overexpressing advanced gastric/GEJ adenocarcinoma?

Key Findings:

• Confirmed ORR of 89.5% (95% CI 78.5–96.0%) across all HER2 IHC 2+/3+ patients, including ISH-negative and PD-L1 CPS <1 subgroups
• Median PFS 13.8 months and median OS 31.9 months at 28.2 months follow-up — substantially exceeding outcomes typical of trastuzumab-based first-line regimens
• Grade ≥3 treatment-related adverse events in 64.9%, predominantly haematological toxicity and peripheral neuropathy

Clinical Relevance: These efficacy signals are striking for a HER2-overexpressing gastric cancer population and could inform future first-line ADC-immunotherapy combinations relevant to NHS patients where trastuzumab plus chemotherapy remains standard of care.

Limitations: Absence of a control arm precludes definitive efficacy conclusions; randomised validation is required before practice change.